LDS/Medical Tests/Hepatitis B Virus (HBV) Genotyping

Hepatitis B Virus (HBV) Genotyping

Hepatitis B virus (HBV) is a member of hepadnaviruses and is a major cause of liver disease. Infection with HBV leads to a variety of conditions including an asymptomatic chronic state, acute self-limited infection, and fulminant hepatitis. Persistent HBV infection is strongly associated with hepatocellular carcinoma. Persons at greatest risk of acquiring HBV infection include: parenteral drug users, men and women with multiple sex partners, patients receiving plasma-derived products, infants born to HBV-infected mothers, and persons living in endemic areas.

The serologic course of HBV infection begins approximately 6 to 10 weeks after infection with the appearance of HBsAg (hepatitis B surface antigen) and HBeAg (hepatitis B envelope antigen), markers of active HBV replication. HBV DNA may be detectable in serum up to 21 days before the appearance of HBsAg. Patients then exhibit increased serum aminotransferase levels, usually ≥ 500 U/L, with the serum alanine aminotransferase (ALT) typically higher than the aspartate aminotransferase (AST) level. Approximately 10 weeks after exposure to HBV, patients may develop nonspecific symptoms such as fatigue and malaise as well as right upper quadrant pain and jaundice. At this time, antibody to hepatitis B core antigen (anti-HBc) of the IgM class appears. In the recovery phase of HBV infection, serum aminotransferase levels return to normal, HBeAg disappears, antibody to HBeAg (anti-HBe) appears, and ultimately HBsAg seroconversion with antibody to HBsAg (anti-HBs) occurs. IgM anti-HBc levels begin to decline as levels of anti-HBc of the IgG class rise in serum. Recovery from acute HBV infection is typically associated with undetectable serum levels of HBV DNA.

Prompt, accurate diagnosis is critical for assessing infectivity and evaluating the prognosis for HBV-infected individuals. HBV laboratory assays include a comprehensive profile of hepatitis related antibodies and antigens for screening, diagnosis, prognosis, and therapeutic monitoring of patients.

Hepatitis serology testing can be used as an aid in the diagnosis of individuals with acute or chronic HBV infection as well as evaluation of serologic conversion to determine immunity status following exposure or vaccination. It is recommended that serology be confirmed by molecular testing that detects viral DNA, which then indicates viral replication. The recommended method is ultrasensitive real-time PCR quantitative assay that detects and quantifies viral DNA. Since HBV has the capability to mutate, it is best to do viral genotyping before treatment.

HBV genotyping is a critical factor in determining disease progression and tailoring antiviral therapy. This assay provides reliable sequencing of the HBV reverse transcriptase (RT) region of the polymerase gene and the HBsAg-encoding region. These regions are essential for identifying genotypes A to H, which are linked to variations in treatment response, resistance profiles, and disease outcomes.

This test is designed to provide clinicians and researchers with detailed genotype-specific insights to optimize HBV management strategies.

  • Treatment Guidance: Certain genotypes respond better to specific therapies, such as interferon or nucleotide analogs
  • Disease Prognosis: Genotypes influence the risk of complications, such as cirrhosis or hepatocellular carcinoma
  • Epidemiological Insights: Tracks genotype distribution and mixed infections

Resistance and surface antigen mutations are reported. Detected mutations in tested genes would indicate resistance to drugs.

The following mutations are reported: reverse transcriptase L80I/V, Il69T, V173L, L180M, A181S/T/V, T184A/C/F/I/G/S/M/L, S202C/G/I, M204I/V, N236T, M250I/L/V; surface antigen P120T, D144A, G145R.

Negative for mutations analyzed

Conventional sequencing, Next generations sequencing (NGS), Hybridization Assay (e.g., INNO-LiPA HBV Genotyping.

Plasma (EDTA).

Stability

  • Ambient: 1-3 days
  • Refrigerated: 7-14 days
HBV DNA by PCR (quantitative), HBsAg, HBeAg, Anti-HBe, HAV antibody, HCV antibody, Liver panel, Acute Hepatitis Profile, Lactate Dehydrogenase, Liver biopsy.
3-7 days.
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
  • Int J Mol Sci. 2024 May 17;25(10):5481. [PMID: 38791519]
  • Rev Med Virol. 2004 Jan-Feb;14(1):3-16. [PMID: 14716688}
  • Expert Rev Mol Diagn. 2021 Apr;21(4):381-396. [PMID:33880971]
  • Clin Liver Dis. 2004;8:267. [PMID: 15481340]
  • Gastroenterol Clin Biol. 2008 Jan;32(1 Pt 2):S56-63. [PMID: 18662611]
  • N Engl J Med. 2004 Mar 11;350(11):1118-29. [PMID: 15014185]
  • Stevens, CD. Clinical Immunology & Serology A Laboratory Perspective 3rd edition. Philadelphia: F.A. Davis Company (2010).
  • Burtis C, Ashwood E, and Bruns D. Fundamentals of Clinical Chemistry. St. Louis: Saunders (2008).